GlassScriptPhysician profile
Jessica Danielle Schmidt
NPI 1073029740
$4,531.52
in general payments reported to CMS, 2019-2025
43 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $368 · 2023: $1,112 · 2024: $1,326 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.43 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $518.90 | 2024-2025 | Omnipod |
| Amgen INC. | $342.30 | 2023-2025 | Prolia, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.56 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $269.25 | 2023-2025 | |
| Dexcom, INC. | $264.84 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Novo Nordisk INC | $255.58 | 2023-2025 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $209.16 | 2023-2025 | Ingrezza |
| Tandem Diabetes Care, INC. | $202.39 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $197.98 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Mallinckrodt Hospital Products INC. | $171.60 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $153.22 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.63 | 2022-2025 | |
| Abbott Laboratories | $150.99 | 2023-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $115.98 | 2022-2024 | Injectafer |
| Incyte Corporation | $99.00 | 2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $89.61 | 2023-2025 | Tarpeyo |
| Medtronic, INC. | $85.04 | 2022-2025 | Intellis Adaptivestim, Minimed 780g, Minimed 770g |
| Corcept Therapeutics | $82.08 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $78.79 | 2022-2023 | Trelegy Ellipta, Nucala, Jemperli |
| Astrazeneca Pharmaceuticals LP | $78.40 | 2024-2025 | Farxiga |
| Averitas Pharma INC. | $68.74 | 2023 | Qutenza |
| Astellas Pharma US INC | $60.12 | 2023-2024 | Veozah |
| Cequr Corporation | $59.80 | 2024-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $55.27 | 2023-2024 | Tirosint, Licart, Tirosint |
| Beta Bionics, INC. | $48.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $40.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.53 | 2022-2024 | Opdualag |
| Xeris Pharmaceuticals, INC. | $30.29 | 2024-2025 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $29.06 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $26.67 | 2023 | Gattex |
| Myriad Genetic Laboratories, INC. | $24.47 | 2022 | |
| Kyowa Kirin, INC. | $21.91 | 2024 | Crysvita |
| Boston Scientific Corporation | $21.39 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.97 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $20.81 | 2025 | Jynarque |
| Genzyme Corporation | $20.11 | 2022 | |
| Chiesi USA, INC. | $19.61 | 2025 | Elfabrio |
| Antares Pharma, INC. | $18.71 | 2024 | Xyosted |
| Apellis Pharmaceuticals, INC. | $18.38 | 2025 | Empaveli |
| Vifor Pharma, INC. | $18.11 | 2023 | Veltassa |
| Sobi, INC | $15.76 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.71 | 2022 | |
| Celgene Corporation | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.